Company: GCL
Filing Date: 2025-08-27
Form Type: DRS
Source: 0001213900-25-080905
Chunk: 339

Company: GCL Global Holdings Ltd
Filing Date: 2025-08-27
Form: DRS
Chunk 339
---
 vendor under that agreement.

On May 21, 2025, the Company
entered into a securities purchase agreement (the “PIPE Investor SPA”) with PIPE Investor Partners (“PIPE Investor”)
for the issuance of senior unsecured convertible notes, through a facility of up to $45.5 million. Pursuant to the PIPE Investor SPA,
the Company has issued and sold to PIPE Investor an initial note in the aggregate original principal amount of $2,900,000, at a purchase
price of $2,610,000 on May 22, 2025. Pursuant to the PIPE Investor SPA, as amended on August 26, 2025, the Company has agreed to issue
and sell to PIPE Investor an additional Note in the original principal amount of $2,530,000 on the date of the submission of this registration
statement by the Company to the SEC.

In connection with that
certain Facility Agreement for a financing of up to SGD5,000,000, the Company issued to Oversea-Chinese Banking Corporation Limited (“OCBC”)
on July 7, 2025 a warrant (the “OCBC Warrant”) to purchase up to 899,281 ordinary shares of the Company at an exercise price
of US$4.17 per share to meet one of the conditions precedent for the Borrower to draw down funds under the Facility Agreement. On July
29, 2025, the Company and OCBC entered into Amendment No. 1 to the OCBC Warrant to clarify their commercial understanding that none of
the terms of the OCBC Warrant shall have any legal effect on the Company unless and until the entire SGD 5,000,000 has been disbursed
by OCBC under the Facility Agreement. As of the date of this prospectus, no fund has been disbursed under the Facility Agreement.

Pursuant to a Subscription
Agreement dated August 22, 2025 with Ronald Teng (“Teng”), the Managing Director of Ban Leong Technologies Limited, an indirect
wholly-owned subsidiary of the Company, the Company has agreed to sell and issue to Teng 625,000 ordinary shares at $4.00 per share, above
the then trading price of the ordinary shares, in a private placement.

<div align='center'>II-1</div>

Item 8. Exhibits and Financial Statement Schedules

| 3.1    
 4.1    |     | Amended                                                                                                                                          
 and Restated Memorandum